RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
I-Mab Biopharma, a Shanghai-San Diego biopharma, announced its US partner, Tracon Pharma, has begun a US Phase I clinical trial of I-Mab’s CD73 antibody in patients with advanced solid tumors. TJD5 is a novel antibody that blocks CD73, a highly immunosuppressive surface enzyme on cancer cells. In the first-in-human trial, TJD5 will be dosed as a single agent and in combination with Tecentriq®, a Roche PD-L1 antibody. I-Mab intends to start similar China trials of TJD5 as well. Source: China Biotoday
